This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Accumulating evidence suggests that the stem cell markers CD133 and CD44 indicate molecular subtype in Glioblastoma Multiforme (GBM). Gene coexpression analysis of The Cancer Genome Atlas GBM dataset was undertaken to compare markers of the Glioblastoma Stem-Progenitor Cell (GSPC) phenotype. Pearson correlation identified genes coexpressed with stem cell markers, which were then used to build a gene signature that classifies patients based on a CD133 coexpression module signature (CD133-M) or CD44-M subtype. ...
Despite improved knowledge and advanced treatments of high-grade gliomas, the overall survival rate ...
BACKGROUND: Experimental data suggest that glioblastoma cells expressing the stem cell marker CD133 ...
Glioblastoma multiforme (GBM) remains refractory to conventional therapy. CD133+ GBM cells have been...
Accumulating evidence suggests that the stem cell markers CD133 and CD44 indicate molecular subtype ...
Accumulating evidence suggests that the stem cell markers CD133 and CD44 indicate molecular subtype ...
Accumulating evidence suggests that the stem cell markers CD133 and CD44 indicate molecular subtype ...
Glioblastoma (GBM) is a heterogeneous tumor of the brain with a poor prognosis due to recurrence and...
Glioblastoma (GBM) is a heterogeneous tumor of the brain with a poor prognosis due to recurrence and...
CD133 can be a marker of tumorigenic CSCs (cancer stem cells) in human GBM (glioblastoma multiforme)...
CD133 can be a marker of tumorigenic CSCs (cancer stem cells) in human GBM (glioblastoma multiforme)...
CD133 can be a marker of tumorigenic CSCs (cancer stem cells) in human GBM (glioblastoma multiforme)...
<div><p>In this manuscript, we use genetic data to provide a three-faceted analysis on the links bet...
Glioblastoma (GBM) is a heterogeneous tumor of the brain with a poor prognosis due to recurrence and...
In this manuscript, we use genetic data to provide a three-faceted analysis on the links between mol...
Glioblastoma is a common, malignant brain tumor whose disease incidence increases with age. Glioblas...
Despite improved knowledge and advanced treatments of high-grade gliomas, the overall survival rate ...
BACKGROUND: Experimental data suggest that glioblastoma cells expressing the stem cell marker CD133 ...
Glioblastoma multiforme (GBM) remains refractory to conventional therapy. CD133+ GBM cells have been...
Accumulating evidence suggests that the stem cell markers CD133 and CD44 indicate molecular subtype ...
Accumulating evidence suggests that the stem cell markers CD133 and CD44 indicate molecular subtype ...
Accumulating evidence suggests that the stem cell markers CD133 and CD44 indicate molecular subtype ...
Glioblastoma (GBM) is a heterogeneous tumor of the brain with a poor prognosis due to recurrence and...
Glioblastoma (GBM) is a heterogeneous tumor of the brain with a poor prognosis due to recurrence and...
CD133 can be a marker of tumorigenic CSCs (cancer stem cells) in human GBM (glioblastoma multiforme)...
CD133 can be a marker of tumorigenic CSCs (cancer stem cells) in human GBM (glioblastoma multiforme)...
CD133 can be a marker of tumorigenic CSCs (cancer stem cells) in human GBM (glioblastoma multiforme)...
<div><p>In this manuscript, we use genetic data to provide a three-faceted analysis on the links bet...
Glioblastoma (GBM) is a heterogeneous tumor of the brain with a poor prognosis due to recurrence and...
In this manuscript, we use genetic data to provide a three-faceted analysis on the links between mol...
Glioblastoma is a common, malignant brain tumor whose disease incidence increases with age. Glioblas...
Despite improved knowledge and advanced treatments of high-grade gliomas, the overall survival rate ...
BACKGROUND: Experimental data suggest that glioblastoma cells expressing the stem cell marker CD133 ...
Glioblastoma multiforme (GBM) remains refractory to conventional therapy. CD133+ GBM cells have been...